C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 16/32 (2006.01) A01K 67/027 (2006.01) A61K 39/395 (2006.01) A61P 35/00 (2006.01) C12N 5/10 (2006.01) C12N 15/13 (2006.01) C12N 15/63 (2006.01)
Patent
CA 2659631
The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to ErbB2, preferably human ErbB2. In another embodiment, the antibodies or antigen-binding portions thereof inhibit ErbB2. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins or portions thereof derived from human anti-ErbB2 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-ErbB2 antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
La présente invention concerne des anticorps, y compris des anticorps humains et leurs fractions de liaison antigénique, qui se lient spécifiquement à l'ErbB2, de préférence l'ErbB2 humain. Dans un autre mode de réalisation, les anticorps ou leurs fragments de liaison antigénique inhibent l'ErbB2. L'invention concerne donc des anticorps qui sont des anticorps monocaténaires bi-spécifiques dérivés chimériques ou des parties de protéines de fusion. L'invention concerne également des immunoglobulines isolées à chaînes lourdes et légères ou des fragments de celles-ci dérivés d'anticorps anti-ErbB2 humains, ainsi que des molécules d'acides nucléiques codant pour ces immunoglobulines. La présente invention concerne également des procédés d'utilisation des anticorps et leurs compositions pour le diagnostic et le traitement. L'invention proposeconcerne aussi des procédés de thérapie génique qui utilisent des molécules d'acides nucléiques codant pour les molécules d'immunoglobulines lourdes et/ou légères qui constituent les anticorps anti-ErbB2 humains. Enfin, l'invention concerne des animaux ou des plantes transgéniques qui comprennent les molécules d'acides nucléiques de la présente invention.
Cartlidge Susan Ann
Dong Jianying
Foltz Ian
Hickinson Mark
Kang Jaspal Singh
Astrazeneca Ab
Smart & Biggar
LandOfFree
Antibodies to erbb2 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies to erbb2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to erbb2 will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1551386